Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00688428 | Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination | PHASE1 | COMPLETED | 84 | — | — | Apr 1, 2008 | Apr 1, 2008 | Mar 12, 2009 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | combination capsule of Esomeprazole 40mg + ASA 325mg |
| 2 | EXPERIMENTAL | Esomeprazole 40 mg capsule and ASA 325 mg tablet |
| Name | Type | Description |
|---|---|---|
| Esomeprazole 40mg/ASA 325mg | DRUG | combination capsule, administered as a single oral dose |
| Esomeprazole | DRUG | 40mg capsule, administered as a single dose |
| ASA | DRUG | 325mg tablet, administered as a single oral dose |
Inclusion Criteria: * Body mass index of 19-29kg/m2, inclusive * Weight of 50-95kg, inclusive * Clinically normal physical findings and laboratory values including hepatitis B, hepatitis C, and HIV, as judged by the Investigator Exclusion Criteria: * Significant clinical illness within the 2 week...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| MediWound Ltd. | MDWD | 1 | PHASE2 | EscharEx |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | NA | Undisclosed |
| Skye Bioscience, Inc. | SKYE | 1 | NA | Undisclosed |